Jennifer Yu, MD, PhD
Staff
co-Leader, Developmental Therapeutics Program
Location: Cleveland Clinic Main Campus
Research
The mission of the Yu lab is to improve therapy for patients with brain tumors by elucidating the molecular mechanisms driving cancer initiation and progression, and in doing so, promote rigorous science and train the next generation of scientists and physicians. Brain tumors fall into two categories, primary brain tumors, which originate in the brain, and brain metastases. Our major area of research is in glioblastoma, the most common primary malignant brain tumor. Our laboratory has made seminal contributions in the understanding of the glioblastoma cellular hierarchy as it relates to different microenvironmental contexts. Glioma stem cells (GSCs) reside in different niches, including the perivascular and hypoxic niches. My laboratory has found that GSCs in different niches utilize distinct pathways to maintain stemness. We have discovered new mechanisms of regulation of two of the most important stem cell regulatory pathways, the Notch and Wnt pathways, in GSCs in these different niches (Cell Stem Cell, Cell Reports, Nature Communications). As a result, tailored approaches are needed to kill GSC populations in the different niches. This is an important concept with significant clinical ramifications. Ongoing projects aim to identify novel drivers of GSC progression and therapeutic resistance.
My patients have impressed upon me the urgent need for better treatments. My laboratory research, therefore, is geared toward having a direct impact in clinical care. To this end, we have launched two investigator-initiated clinical trials (IITs) based on our work. One clinical trial (NCT02970448) is based our work showing that hyperthermia not only sensitizes GSCs to radiation but also suppresses radiation-induced survival signaling. Our clinical trial demonstrates the safety and efficacy of expediting chemoradiation after laser hyperthermia for patients with GBM to take advantage of the radiosensitization of GSCs, improved penetration of chemotherapy due to disruption of the blood brain barrier, and augmented anti-tumor immune response. This trial has the potential to change standard of care.
Our studies and that of our colleagues in the field of cancer neuroscience highlight crosstalk between nerves and cancer cells. These studies led to our clinical trial investigating electrical activity at the interface of “normal brain” and tumor in patients with GBM. This trial tests the hypothesis that the extent and pattern of electrical activity can predict future sites of disease progression and therefore inform regions for supramarginal tumor resection and radiotherapy intensification (NCT05565118). This is the first clinical trial to combine deep electrode recordings at the brain-tumor interface along with site directed biopsies at sites of electrical recordings to define the quality and extent of electrical signaling on tumor progression and its mechanistic basis.
Biography
Dr. Jennifer Yu is a Staff in the Department of Radiation Oncology, Department of Cancer Biology, Center for Cancer Stem Cell Biology at the Cleveland Clinic, and co- Leader of the Developmental Therapeutics Program and co-Leader of the Cancer Stem Cell Working Group at the NCI-designated Case Comprehensive Cancer Center. She specializes in radiation oncology with a focus on brain tumors. She is the Founding Director of the Center for Hyperthermia at the Cleveland Clinic.
Education & Professional Highlights
Dr. Yu completed her MD and PhD degrees at Columbia University and radiation oncology residency at the University of California, San Francisco. She has served as President of the Society for Thermal Medicine, Radiation Oncology Representative of the Society for Neuro-Oncology, and serves on the American Brain Tumor Association Clinical Advisory Board. Dr. Yu was named a Top Oncologist by Ohio Magazine, a recipient of the Gita Gidwani Mid-Career Leadership Fellowship, Lerner Rising Star Award, Cleveland Clinic Excellence in Science Award, George W. Crile, Sr. Founder's Award, and is a member of Council of the American Society for Clinical Investigation.
"CIMER Trained Mentor" indicates the principal investigator has completed mentorship training based on curriculum from the Center for the Improvement of Mentored Experiences in Research, aimed at advancing mentoring relationships and promoting cultural change in research.
Research
Ongoing Research Directions
Glioma stem cells (GSCs) are a subpopulation of cells that contribute to tumor progression and therapeutic resistance. GSCs have a high capacity for self-renewal, survival under hypoxic conditions, resistance to radiation and chemotherapy, and high invasive potential. GSCs reside in specialized niches that facilitate cell-cell and cell-microenvironmental conditions that maintain stemness and resistance to treatments.
Our lab is focused on delineating the molecular mechanisms underlying stem cell maintenance and therapeutic resistance of GSCs in different niches. Our long long-term goal is to uncover therapeutic vulnerabilities and target these pathways in clinic. We employ a number of approaches including multi-omic approaches, ribosome profiling, molecular biology, mouse modeling and human tissue analyses. Major areas of studies include the following:
1. GSC maintenance and cell state plasticity. GSCs share many properties with normal stem cells. We aim to understand mechanisms by which GSCs re-activate core developmental pathways, including the Semaphorin, Notch, Wnt, TGFbeta pathways, and cross-talk between these pathways. We also assess epigenetic regulation of cell state plasticity to inform therapeutic strategies of cellular differentiation for GBM.
2. GSC adaptations to hypoxia. GSCs frequently reside in a hypoxic niche. These GSCs are particularly resistant to treatment since clinically relevant radiation is dependent on oxygen, and chemotherapy is unable to be delivered to these areas. The hypoxia inducible factors (HIFs) integrate many cellular responses to hypoxia. We aim to understand HIF- dependent and independent mechanisms that contribute to GSC survival and therapeutic resistance. Current efforts include assessing an important yet poorly understood level of regulation: translation of genes involved in the hypoxic stress response. We are also investigating the role of hypoxia-regulated proteins and non-coding RNAs in GSC response to hypoxia.
3. Neural regulation of cancers. Many cancers including glioblastoma invade along axon tracks. We identified the secreted axonal guidance cue Sema3C and its receptor complex NRP1-PlxnD1 as an important pathway that is selectively used by glioma stem cells to promote their own cell survival and invasion. This pathway facilitates short range communication amongst glioma stem cells to maintain the GSC population and drive their invasion and resistance to radiation. We also lead a clinical trial (NCT05565118) in which we evaluate electrical activity around glioblastoma at the time of surgery and stereotactic biopsies at those sites of activity, with the goal of developing electrophysiological biomarkers of progress and uncovering activity-dependent mechanisms of glioblastoma progression. We collaborate with our neurosurgical, neuroengineering, and neuroradiology colleagues to assess interactions and electrical activity between cancer cells, neurons, and immune cells in human GBM.
4. Effects of the microbiome in cancer progression. The microbiome is increasingly recognized for its role in cancer initiation and modulating responses to chemotherapy and immunotherapy. Current efforts focus on illuminating the role of the microbiome on radiation response in patients with glioblastoma.
5. Radiosensitization strategies. GSCs are highly resistant to radiation due to upregulation of pro-survival signaling and enhanced DNA damage repair capacity. We are interested in improving the radiosensitivity of GSCs with thermal therapy, modifications in radiation delivery and radiosensitizing drugs.
Our Team
Selected Publications
Bharti Rashmi, Dey Goutam, Khan Debjit, Myers Alex, Huffman Olivia G, Saygin Caner, Braley Chad, Richards Elliott, Sangwan Naseer, Willard Belinda, Lathia Justin D, Fox Paul L, Lin Feng, Jha Babal Kant, Brown J Mark, Yu Jennifer S, Dwidar Mohammed, Joehlin-Price Amy, Vargas Roberto, Michener Chad M, Longworth Michelle S, Reizes Ofer. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024. 38853277.
Murphy Erin S, Yang Kailin, Suh John H, Yu Jennifer S, Stevens Glen, Angelov Lilyana, Barnett Gene H, Neyman Gennady, Mohammadi Alireza M, Chao Samuel T. Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases. Neuro Oncol. 2024. 38656347.
Huang Haidong, Shah Hariti, Hao Jing, Lin Jianhong, Prayson Richard A, Xie Liangqi, Bao Shideng, Chakraborty Abhishek A, Jankowsky Eckhard, Zhao Jianjun, Yu Jennifer S. LncRNA LUCAT1 Promotes Glioblastoma Progression by Enhancing HIF1α Activity. Neuro Oncol. 2024. 38456228.
Tom Martin C, DiFilippo Frank P, Jones Stephen E, Suh John H, Obuchowski Nancy A, Smile Timothy D, Murphy Erin S, Yu Jennifer S, Barnett Gene H, Angelov Lilyana, Mohammadi Alireza M, Huang Steve S, Wu Guiyun, Johnson Scott, Peereboom David M, Stevens Glen H J, Ahluwalia Manmeet S, Chao Samuel T. F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study. J Neurooncol. 2023. 37341842.
Hao Jing, Han Xiangzi, Huang Haidong, Yu Xingjiang, Fang Jiankang, Zhao Jianjun, Prayson Richard A, Bao Shideng, Yu Jennifer S. Sema3C signaling is an alternative activator of the canonical WNT pathway in glioblastoma. Nat Commun. 2023. 37080989.
Gorenflo Maria P, Shen Alan, Murphy Erin S, Cullen Jennifer, Yu Jennifer S. Area-level socioeconomic status is positively correlated with glioblastoma incidence and prognosis in the United States. Front Oncol. 2023. 37007113.
Billena Cole, Lobbous Mina, Cordova Christine A, Peereboom David, Torres-Trejo Alejandro, Chan Timothy, Murphy Erin, Chao Samuel T, Suh John, Yu Jennifer S. The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases. Front Oncol. 2023. 36910642.
. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest. 2022. 36125896.
Lauko Adam, Volovetz Josephine, Turaga Soumya M, Bayik Defne, Silver Daniel J, Mitchell Kelly, Mulkearns-Hubert Erin E, Watson Dionysios C, Desai Kiran, Midha Manav, Hao Jing, Bao Shideng, Yu Jennifer S, Lathia Justin D. SerpinB3 drives cancer stem cell survival in glioblastoma. Cell Rep. 2022. 36103817.
Tewari Surabhi, Park Deborah Y J, Wei Wei, Chao Samuel T, Yu Jennifer S, Suh John H, Kilic Sarah, Peereboom David M, Stevens Glen H J, Lathia Justin D, Prayson Richard, Barnett Gene H, Angelov Lilyana, Mohammadi Alireza M, Murphy Erin S. Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome. Int J Radiat Oncol Biol Phys. 2022. 35667529.
Park Deborah Y, Chen Yanwen, Tewari Surabhi, Yu Jennifer S, Chao Samuel T, Suh John H, Peereboom David M, Stevens Glen H J, Barnett Gene H, Angelov Lilyana, Mohammadi Alireza, Hogan Thomas, Kissel Courtney, Lapin Brittany, Schuermeyer Isabel, Naugle Richard, Murphy Erin S. Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. J Neurooncol. 2022. 35486307.
Park Deborah Y, Wei Wei, Tewari Surabhi, Yu Jennifer S, Chao Samuel T, Suh John H, Peereboom David, Stevens Glen H J, Barnett Gene H, Angelov Lilyana, Mohammadi Alireza M, Hogan Thomas, Kissel Courtney, Lapin Brittany, Schuermeyer Isabel, Naugle Richard, Murphy Erin S. Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. J Neurooncol. 2022. 35064450.
Knackstedt Rebecca, Smile Timothy, Yu Jennifer, Gastman Brian R. Non-Operative Options for Loco-regional Melanoma. Clin Plast Surg. 2021. 34503723.
Hao Jing, Buck Matthias, Yu Jennifer S. Interactions between semaphorins and plexin-neuropilin receptor complexes in the membranes of live cells. J Biol Chem. 2021. 34270956.
Fang Xiaoguang, Huang Zhi, Zhai Kui, Huang Qian, Tao Weiwei, Almasan Alexandru, Yu Jennifer S, Li Xiaoxia, Stark George R, Bao Shideng. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. Sci Transl Med. 2021. 34193614.
Yu Jennifer S. Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery. 2021. 33862619.
Huang Haidong, Yu Xingjiang, Han Xiangzi, Hao Jing, Zhao Jianjun, Bebek Gurkan, Bao Shideng, Prayson Richard A, Khalil Ahmad M, Jankowsky Eckhard, Yu Jennifer S. Piwil1 Regulates Glioma Stem Cell Maintenance and Glioblastoma Progression. Cell Rep. 2021. 33406417.
Hu Yi, Amorim Tania, Maqbool Mohsin, Li Chen, Fang Chuanfeng, Fang Hua, Yin Mei, Janocha Allison J, Mejia-Garcia Alex, Anwer Faiz, Khouri Jack, Qi Xin, Zheng Qing Y, Yu Jennifer S, LaFramboise Thomas, Herlitz Leal C, Lin Jianhong, Zhao Jianjun. Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021. 33288657.
Tao Weiwei, Zhang Aili, Zhai Kui, Huang Zhi, Huang Haidong, Zhou Wenchao, Huang Qian, Fang Xiaoguang, Sloan Andrew E, Ahluwalia Manmeet S, Lathia Justin D, Yu Jennifer S, Bao Shideng. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Mol Med. 2020. 33124191.
McCallum Grant A, Shiralkar Jay, Suciu Diana, Covarrubias Gil, Yu Jennifer S, Karathanasis Efstathios, Durand Dominique M. Chronic neural activity recorded within breast tumors. Sci Rep. 2020. 32908180.
Yu Jennifer S, Mohammadi Alireza M. Introduction to laser thermal therapy for brain disorders. Int J Hyperthermia. 2020. 32672120.
Zhang Aili, Tao Weiwei, Zhai Kui, Fang Xiaoguang, Huang Zhi, Yu Jennifer S, Sloan Andrew E, Bao Shideng. Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy. Neuro Oncol. 2020. 32592588.
Tao Weiwei, Chu Chengwei, Zhou Wenchao, Huang Zhi, Zhai Kui, Fang Xiaoguang, Huang Qian, Zhang Aili, Yu Xingjiang, Huang Haidong, Sloan Andrew E, Yu Jennifer S, Li Xiaoxia, Stark George R, Bao Shideng. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. Nat Commun. 2020. 32541784.
Dharmaiah Sharvari, Zeng Johnathan, Rao Vinay S, Zi Ouyang, Ma Tianjun, Yu Kevin, Bhatt Heeruk, Shah Chirag, Godley Andrew, Xia Ping, Yu Jennifer S. Clinical and dosimetric evaluation of recurrent breast cancer patients treated with hyperthermia and radiation. Int J Hyperthermia. 2019. 31544546.
Tom Martin C, Park Deborah Y J, Yang Kailin, Wei Wei, Jia Xuefei, Varra Vamsi, Yu Jennifer S, Chao Samuel T, Balagamwala Ehsan H, Suh John H, Barnett Gene H, Prayson Richard A, Stevens Glen H J, Peereboom David M, Ahluwalia Manmeet S, Murphy Erin S. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2019. 31461674.
Kay KE, Lee J, Hong ES, Belis J, Dayal S, Wesley E, Wang SZ, Dilver DJ, Volovetz J, Johnson S, McGraw M, Grabowski MM, Lu T, Freytag L, Narayana V, Freytag S, Best S, Whittle J, Wang Z, Reizes O, Yu JS, Hazen SL, Brown JM, Bayik D, Lathia JD. Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment via CD8+ T cell inhibition in glioblastoma. Journal of Clinical Investigation. 2025;135(2):e177824.
Yu JS, Meade S, Zhao R, Wei W, Dashora H, Prayson R, Grabowski M, Mohammadi AM. Expedited Chemotherapy and Radiation After Laser Interstitial Thermal Therapy is Safe and Efficacious in Patients with Newly Diagnosed High-Grade Glioma. Neuro-Oncology Advances. 2025 Feb. vdaf038
Bommireddy A, Mayo Z, Reddy C, Billena C, Davies EM, Davis RW, Murphy ES, Suh JH, Balgamwala E, Chan TA, Yu JS, Barnett GH, Angelov A, Mohammadi AM, Stevens G, Grawbowski M, Peereboom D, Chao ST. Development of a Recursive Partitioning Analysis for Prediction of Radiation Necrosis Following Single Fraction Stereotactic Radiosurgery for Intact Brain Metastases. Journal of Neuro-Oncology. 2025 Sep;174(2):503-510.
Wang Q, Irons EE, Zhang W, Zhao F, Chang MH, Dai E, Jeon J, Hong H, Maeda R, Kim M, Emhoff K, Yin M, Willard B, Zheng QY, Prayson R, Beach J, Yu JS, Hu B, Zhao J, Lin J. Cisplatin-induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss. Cancer Research Communications. 2025 Jun 1;5(6)994-1007.
Liu Y, Pang L, Khan F, Wu J, Zhou F, Horbinski C, Bao S, Yu JS, Lathia J, Chen P. Glycoprotein-NMB mediates symbiotic GSC-TAM interaction to promote tumor progression. JCI Insight. 2025;10(13):e187684
Rock V, Ahluwalia M, Anthony M, Arons D, Arzbaecher J, Claus EB, Dunbar E, Fraher C, Freund M, Gondi V, Goss C, Greene B, Chas Haynes C, Khanuja. S, Laubacher MA, Leach D, Loughan A, Mammoser T, Musella A, Oliver K, Paabo K, Puduvalli V, Shaffer G, Thomas AA, Wallgren K, Watson C, Wefel JS, Yu JS, Zada G, Willmarth N, DeVitto R. Guiding Principles for Adult CNS Tumor Treatment Programs. Neuro-Oncology Advances, 2025: 7(1) vdaf169.
Zhang Z, Wang C, Zhao Z, Yi Z, Durmaz A, Yu JS, Bebek G, nSEA: n-Node Subnetwork Enumeration Algorithm Identifies Lower Grade Glioma Subtypes with Altered Subnetworks and Distinct Prognostics. Pacific Symposium on Biocomputing. 2024;29:521-533.
Huang H, Shah H, Hao J, Lin J, Prayson RA, Xie L, Bao S, Chakraborty AA, Jankowsky E, Zhao J, Yu JS*, LncRNA LUCAT1 promotes glioblastoma progression by enhancing HIF1⍺ activity. Neuro-Oncology. 2024 March 8:noae036. Commentary on this article: Zhang Y, Hudon K, Abounader R, Unraveling the hypoxic puzzle: lncRNA LUCAT1 drives glioblastoma in cooperation with HIF1a, Neuro Oncol 2024 May 21;26(8):1402-1404.
Murphy ES, Yang K, Suh JH, Yu JS, Schilero C, Stevens G, Angelov L, Vogelbaum M, Barnett GH, Ahluwalia M, Neyman G, Mohammadi AM, Chao ST, Phase I Trial of Dose Escalation for Pre-Operative Radiosurgery for Patients with Large Brain Metastases. Neuro-Oncology. 2024 April 24:noae076.
Bharti R, Dey G, Khan D, Myers A, Huffman OG, Saygin C, Braley C, Richards E, Sangwan N, Lathia JD, Fox PL, Lin F, Jha B. Brown JM, Yu JS, Dwidar M, Joehlin-Price A, Vargas R, Michener CM, Longworth MS, Reizes O. Cell Surface CD55 Tracks to the Nucleus Leading to Cisplatin Resistance and Stemness by Inducing PRC2 and H3K27 Trimethylation on Chromatin in Ovarian Cancer. Molecular Cancer. 2024 June 23:121.
Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, Li JJ, Mueller M, Aggarwal A, Al-Ibrahim A, Alkhatib S, Atun R, Bello A, Bjelac OC, Delgado Bolton RC, Buatti J, Cordero-Mendez L, Eichler T, Fidarova E, Gondhowiardjo S, Gospodarowicz. M, Grover S, Hande V, Harsdorf E, Holmberg O, Jaffray D, Kiess A, Knoll P, Kunikowska J, Lewis JS, Lievens Y, Mayr N, Mikhail M, Olasinde T, Ostwald D, Peristeris P, Xia P, Rosa A, Salem S, Santos M, Sathkege MM, Shrivastava SK, Titovich E, Urbain JL, Vanderpuye V, Wahl R, Yu JS, Zaghloul MS, Zhu H, Scott AM, MD. Lancet Oncology Commission on Radiotherapy and Theranostics. Lancet Oncology. 2024 Nov 25(11)e545-580.
Banerjee R, Wehrle CJ, Wang Z, Wilcox JD, Uppin V, Varadharajan V, Mrejen M, Hershberger C, Reizes O, Yu JS, Lathia JD, Rotroff DM, Hazen SL, Tang WHW, Aucejo F, Brown JM. Circulating Gut Microbe-Derived Metabolites are Associated with Hepatocellular Carcinoma. Biomedicines. 2024 Aug 26;12(9).
Billena C, Lobbous M, Cordova CA, Peereboom D, Torres-Trejo A, Chan T, Murphy E, Chao ST, Suh J, Yu JS, The Role of Targeted Therapy and Immune Therapy in the Management of Non-Small Cell Lung Cancer Brain Metastases. Frontiers in Oncology. 2023; 13, online.
Gorenflo M, Shen A, Murphy ES, Cullen J, Yu JS*, Relationship Between Area-Level Socio-economic Status and Glioblastoma Incidence and Prognosis. Frontiers in Oncology. 2023; 13, online.
Hao J, Huang H, Han X, Yu X, Prayson RA, Bao S, Yu JS, Semaphorin 3C Signaling Is an Activator of the Canonical Wnt Pathway in Glioblastoma. Nature Communications. 2023; 14:2262.
Tom MC, DeFilippo FP, Jones SE, Suh JH, Obuchowski NA, Smile TD, Murphy ES, Yu JS, Barnett GH, Angelov L, Mohammadi AM, Huang SS, Wu G, Johnson S, Peereboom DM, Stevens GHJ, Ahluwalia MS, Chao ST, 18—Fluciclovine PET/CT to Distinguish Radiation Necrosis from Tumor Progression for Brain Metastases Treated with Radiosurgery: Results of a Prospective Pilot Study. Journal of Neuro-Oncology. 2023;163(3)647-655.
Park DY, Tom MC, Wei W, Tewari S, Ahluwalia MS, Yu JS, Chao ST, Suh JH, Peereboom D, Stevens GHJ, Barnett GH, Angelo L, Mohammadi AM, Hogan T, Kissle C, Lapin B, Schuermeyer I, Parsons MW, Naugle R, Murphy ES, Quality of Life Following Concurrent Temozolomide-based Chemoradiation Therapy of Observation in Low Grade Glioma, Journal of Neuro-Oncology. 2022; 156(3):499-507.
Park DY, Tom MC, Chen Y, Tewari S, Ahluwalia MS, Yu JS, Chao ST, Suh JH, Peereboom D, Stevens GHJ, Barnett GH, Angelov L, Mohammadi AM, Hogan T, Kissle C, Lapin B, Schuermeyer I, Parsons MW, Naugle R, Murphy ES, Cognitive Function After Concurrent Temozlomide-based Chemoradiation Therapy in Low Grade Gliomas, Journal of Neuro-Oncology. 2022;158(3):341-348.
Tewari S, Tom MC, Park D, Wei W, Chao ST, Yu JS, Suh JH, Kilic S, Peereboom DM, Stevens G, Lathia JD, Prayson R, Barnett GH, Angelov L, Mohammadi AM, Ahluwalia MS, Murphy ES, Sex-Specific Differences in Low Grade Glioma Presentation and Outcome, International Journal of Radiation Oncology, Biology, Physics, 2022;114(2):283-292.
Lauko A, Volovetz J, Turaga SM, Bayik D, Silver DJ, Mitchell K, Mulkearns-Hubert EE, Watson DC, Desai K, Midha M, Hao J, McCortney K, Steffens A, Naik U, Ahluwalia MS, Bao S, Horbinski C, Yu JS, Lathia JD, SerpinB3 drives cancer stem cell survival in glioblastoma. Cell Reports. 2022;40(11):111348.
Haase S, Banerjee K, Mujeeb AA, Hartlage CS, Nunez FM, Nunez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi M, Taher AW, Brumley EK, Thompson S, Dreyer JT, Alindogan CT, Garcia-Fabiani MB, Comba A, Venneti S, Ravikumar V, Koschmann C, Carcaboso AM, Vinci M, Rao S, Yu JS, Lowenstein PR, Castro MG, H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest. 2022:e154229.
Huang H, Yu X, Han X, Hao J, Zhao J, Bebek G, Bao S, Prayson RA, Khalil AM, Jankowsky E, Yu JS. Piwil1 Regulates Glioma Stem Cell Maintenance and Glioblastoma Progression. Cell Reports. 2021 Jan 5; 34(1):108522
Nduom EK, Gephart MH, Chheda M, Suva ML, Amankulor N, Battiste JD, Campian JL, Dacey RG, Jr., Das S, Fecci PE, Hadjipanayis CG, Hoang KB, Jalali A, Orringer D, Patel AJ, Placantonakis D, Rodriguez A, Yang I, Yu JS, Greg J. Zipfel GJ, Dunn GP, Leuthardt EC, Kim AH, Re-Evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by The Christopher Davidson Forum Investigators. Neurosurgery. 2021 Jun 15; 89(1):129-132.
Fang X, Huang Z, Zhai K, Huang Q, Tao W, Kim L, Wu Q, Almasan A, Yu JS, Li X, Stark G, Rich JN, Bao S, Inhibiting DNA-PK Induces Glioma Stem Cell Differentiation and Sensitizes Glioblastoma to Radiation in Mice. Science Translational Medicine. 2021 June 30; 13(600).
Christie SM, Hao J, Tracy E, Buck M, Yu JS, Smith AW, Interactions Between Semaphorins and Plexin/Neuropilin Receptor Complexes in the Membranes of Live Cells. Journal of Biological Chemistry. 2021 July 13. Online
Knackstedt R, Smile T, Yu JS, Gastman BR, Non-operative Options for Loco-regional Melanoma. Clin Plastic Surg. 2021(48): 631-642.
Tao W, Chu C, Zhou W, Huang Z, Zhai K, Fang X, Huang Q, Zhang A, Wang Z, Yu X, Huang H, Wu Q, Sloan A, Yu JS, Li X, Stark G, Rich J, Bao S, Dual Role of WISP1 in Maintaining Glioma Stem Cells and Tumor-supportive Macrophages in Glioblastoma. Nature Communications. 2020; 11(1):3015
Yu JS, Mohammadi AM, Introduction to Laser Thermal Therapy for Brain Disorders. International Journal of Hyperthermia. 2020; 37(2):1-2 *Corresponding author
McCallum G, Shiralkar J, Suciu D, Covarrubias G, Yu JS, Karathanasis E, Durand D, Chronic neural activity recorded within breast tumors. Scientific Reports. 2020; 10(1):14824
Zhang A, Tao W, Zhai K, Fang X, Huang Z, Yu JS, Sloan AE, Rich JN, Bao S, Protein Sumoylation with SUMO1 Promoted by PIN1 in Glioma Stem Cells Augments Glioblastoma Malignancy. Neuro-Oncology. 2020 Jun27:noaa150.
Tao W, Zhang A, Zhai K, Huang Z, Huang H, Zhou W, Huang Q, Fan X, Prager BC, Wang X, Wu Q, Sloan AE, Ahluwalia MS, Lathia JD, Yu JS. Rich JN, Bao S. SATB2 Drives Glioblastoma Growth by Recruiting CBP to Promote FOXM1 Expression in Glioma Stem Cells. EMBO Molecular Medicine. 2020 Oct 30:e12291
Hu Y, Yang C, Amorim T, Maqbool M, Lin J, Li C, Fang X, Xue L, Kwart A, Fang H, Yin M, Janocha A, Tsuchimoto D, Nakabeppu Y, Jiang X, Mejia-Garcia A, Anwer F, Khouri J, Qi X, Zhang Q, Yu JS, Yan S, LaFramboise T, Anderson K, Herlitz L, Mushi K, Lin J, Zhao J. Cisplatin-mediated Upregulation of Apurinic/Apyrimidinic Endonuclease 2 (APE2) Binding to Myosin Heavy-chain 9 (MYH9) Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Research. 2020 Dec 7
Careers
Research News
Jennifer Yu, MD, PhD, who was recently appointed as a council member for ASCI, shares insights on the importance of tackling disease from both the bedside and the bench.
Drs. Yu and Zhao will study the role of a long non-coding RNA called Lucat1 in glioma stem cells in the search for new therapeutics to help treat glioblastoma and overcome treatment resistance.